GlaxoSmithKline (GSK) Given a GBX 1,340 Price Target by JPMorgan Chase & Co. Analysts

GlaxoSmithKline (LON:GSK) has been given a GBX 1,340 ($17.92) target price by JPMorgan Chase & Co. in a report issued on Thursday. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.’s price objective would suggest a potential downside of 1.54% from the company’s current price.

Other equities research analysts have also issued reports about the stock. Berenberg Bank reaffirmed a “buy” rating and set a GBX 1,835 ($24.54) price objective on shares of GlaxoSmithKline in a report on Tuesday, September 19th. Jefferies Group reaffirmed a “buy” rating on shares of GlaxoSmithKline in a report on Wednesday, September 6th. reaffirmed a “buy” rating and set a GBX 1,970 ($26.34) price objective on shares of GlaxoSmithKline in a report on Wednesday, September 13th. Liberum Capital cut their price objective on shares of GlaxoSmithKline from GBX 1,900 ($25.40) to GBX 1,760 ($23.53) and set a “buy” rating for the company in a report on Wednesday, October 4th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and set a GBX 1,900 ($25.40) price objective on shares of GlaxoSmithKline in a report on Tuesday, October 17th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the stock. GlaxoSmithKline has an average rating of “Hold” and an average price target of GBX 1,563.33 ($20.90).

Shares of GlaxoSmithKline (LON:GSK) opened at GBX 1,361 ($18.20) on Thursday. GlaxoSmithKline has a 52-week low of GBX 1,270 ($16.98) and a 52-week high of GBX 1,724.50 ($23.06). The company has a market cap of $67,480.00 and a PE ratio of 2,835.42.

GlaxoSmithKline (LON:GSK) last released its earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). The company had revenue of GBX 784.30 billion during the quarter. GlaxoSmithKline had a net margin of 17.79% and a return on equity of 461.88%.

In related news, insider Patrick Vallance sold 20,000 shares of the firm’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($17.52), for a total value of £262,000 ($350,314.21). Also, insider Simon Dingemans purchased 1,076 shares of the stock in a transaction that occurred on Thursday, October 12th. The stock was bought at an average price of GBX 1,527 ($20.42) per share, with a total value of £16,430.52 ($21,968.87). Insiders have bought a total of 1,577 shares of company stock valued at $2,400,086 over the last quarter.

COPYRIGHT VIOLATION NOTICE: “GlaxoSmithKline (GSK) Given a GBX 1,340 Price Target by JPMorgan Chase & Co. Analysts” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.com-unik.info/2018/01/06/glaxosmithkline-gsk-given-a-gbx-1340-price-target-by-jpmorgan-chase-co-analysts.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit